, Jong Wan Kim, M.D. 5 , and Hee Gu Lee, Ph.D. Background : Human telomerase reverse transcriptase (hTERT) is a catalytic enzyme that is required for telomerase activity (TA) and cancer progression. Telomerase inhibition or inactivation increases cellular sensitivity to UV irradiation, DNA-damaging agents, the tyrosine kinase inhibitor, imatinib, and pharmacological inhibitors, such as BIBR1532. hTERT is associated with apoptosis. Some patients show drug-resistance during anti-cancer drug treatment and the cancer cell acquire anti-apoptotic mechanism. Therefore, we attempted to study correlation between hTERT and drug-resistance.
Methods : To study the correlation between protein level and activity of hTERT and drug-resistance, Western blotting and telomerase repeat amplification protocol (TRAP) assays were performed. To investigate whether hTERT contributes to drug resistance in tumor cells, we transiently decreased hTERT levels using small interfering RNA (siRNA) in T24/R2 cells.
Results : hTERT knockdown increased Bax translocation into the mitochondria and cytochrome C release into the cytosol. Caspase inhibitors, especially Z-VAD-FMK, rescued this phenomenon, suggesting that the stability or expression of hTERT might be regulated by caspase activity.
Conclusions : These data suggest that hTERT might be a target molecule for drug-resistant tumor therapy. Key Words : Cisplatin, hTERT, Apoptosis, Bladder cancer, Caspase and bladder [1] . Cisplatin induces DNA damage, inhibits DNA synthesis, suppresses RNA transcription, blocks the cell cycle, and induces apoptosis in cancer cells [2] and cisplatinbased combination chemotherapy is a mainstay treatment for metastatic bladder cancer. However, the efficacy of cisplatin-based chemotherapy is limited by de novo drug resistance during chemotherapy [3] . The exact level of cisplatin resistance in patients can be inferred from clinical studies, since responses have been observed when the standard clinical dose of cisplatin was doubled in drug-intensive protocols [4] . In general, resistance to cisplatin may be substantially greater, as judged from studies of tumor cell lines established from clinically refractory tumors, which require cytotoxic concentrations as much as 50-100 fold in excess of those needed for sensitive tumor cells [5] .
Telomerase is a potential diagnostic and prognostic marker in human tumors consisting of a specialized ribonucleoprotein polymerase composed of the RNA subunit, human telomerase RNA (hTR), and a catalytic protein component, human telomerase reverse transcriptase (hTERT), which can elongate telomeric DNA using its own RNA subunit as a template [6] . hTR is ubiquitously and equivalently expressed in both normal and tumor tissues, but the hTERT subunit is selectively expressed in a small subset of normal cells, tumor tissues, and tumor-derived cell lines, indicating that hTERT is the rate-limiting component of telomerase activity (TA) [7] [8] [9] [10] [11] [12] .
With few exceptions, TA and hTERT are found in samples obtained from bladder carcinoma, but not in normal controls. In addition, the hTR template is detected more often and at higher levels in samples obtained from bladder carcinomas than normal controls. Therefore, telomerase can identify both well-differentiated and early-stage bladder tumors [13] [14] [15] [16] . Telomerase inhibition or inactivation increases cellular sensitivity to UV irradiation, DNA-damaging agents, the tyrosine kinase inhibitor, imatinib, and pharmacological inhibitors, such as BIBR1532 [17] [18] [19] [20] . Telomerase inhibition is usually achieved via gene knockout, antisense oligonucleotides, or dominant-negative forms of the telomerase enzyme.
In this study, we investigated the role of hTERT in cisplatin-resistant bladder cancer cells. Acute hTERT depletion using a specific small interfering RNA (siRNA) induced Bax translocation into the mitochondrial membrane and cytochrome C release into the cytosol. Therefore, hTERT inhibition facilitates the induction of apoptosis via the mitochondrial pathway, and suggests that hTERT is critical in chemotherapy of cisplatin-resistant cells.
MATERIALS AND METHODS

Cell lines and culture conditions
The human bladder cancer cell line, T24, was purchased from the American Type Culture Collection (Benethda, MA, USA), and the cisplatin-resistant subcell line, T24/R2, was previously established by the stepwise exposure of T24 cells to 2 μ g/mL of cisplatin [21] . These cell lines were maintained in RPMI-1640 medium (Hyclone, Road Logan, UT, USA) containing 10% FBS and antibiotics at 37℃, in a humidified incubator with an atmosphere of 5% CO2.
Antibodies and reagents
Anti-hTERT and anti-caspase 3 antibodies were pur- 
Cytotoxicity assay
The percentage of viable cells was determined using the TRAP products were run on a 15% non-denaturing polyacrylamide gel electrophoresis (PAGE) gel, and 6 bp telomeric ladder bands were measured by silver staining.
Western blot analysis
For Western blot analysis, cisplatin-treated cells were harvested and lysed in lysis buffer (20 mM Tris, pH 7.4, 2 mM EDTA, 150 mM sodium chloride, 1 mM sodium deoxycholate, 1% Triton X-100, 10% glycerol, 1 mM PMSF, 5 μ g/ mL aprotinin, and 10 μ g/mL leupeptin). Protein concentrations were determined using the Bio-Rad protein assay kit, subjected to 8-15% SDS-PAGE, and transferred onto PVDF membranes (Hybond-P, Amersham Bioscience, Buckinghamshire, England). Subsequently, the membrane was incubated for 2 hr at room temperature in a 5% skim milk solu- 
Flow cytometry analysis of apoptosis
To measure cell death induced by cisplatin, the cells were 
Subcellular fractionation
Cytosolic and membrane-bound organelle fractions were prepared by selective plasma membrane permeabilization with digitonin. In brief, cells were exposed to 0.05% digitonin in an isotonic sucrose buffer (250 mM sucrose, 10 mM HEPES, 10 mM KCl, 1. 
RESULTS
TA and hTERT protein levels are associated with cisplatin-resistance
The T24/R2 cell line had been established by stepwise exposure of T24 cells to 2 μ g/mL of cisplatin to induce resistance to cisplatin [22, 23] . We first performed MTS assays to elucidate the effect of cisplatin-induced apoptosis in T24
and T24/R2 cells. Cisplatin treatment of exponentially growing T24 and T24/R2 cells rapidly decreased the cell viability of T24 cells in a dose-dependent manner but did not affect T24/R2 cells (Fig. 1A) . To test whether hTERT activity is correlated with drug resistance, we exposed T24 and T24/ R2 cells to cisplatin (10 μ g/mL) and measured TA, which requires hTERT. Exposure to cisplatin decreased TA in the TRAP assay of T24 parental cells but not that of T24/R2 cells (Fig. 1B) and decreased hTERT protein levels over time in T24 cells but not T24/R2 cells (Fig. 1C) . Cisplatin also induced bcl-2 expression in T24/R2 cells, as previous
shown [23] , but not T24 cells, and did not affect the other bcl-2 family members, bcl-xL, bax, or bak. Thus, hTERT levels and TA might be involved in cisplatin resistance in T24/R2 cells. leads to reduced bax translocation and cytochrome C release [23, 24] . To test whether hTERT expression affected Bax translocation, we transfected T24/R2 cells with hTERT siRNA using Lipofectamin ( Fig. 2A) . Cisplatin treatment of cells transfected with the siRNA increased bax levels in the mitochondrial membrane fraction and cytochrome C in the cytosol compared to control siRNA cells (Fig. 2B) , suggesting that hTERT depletion affects the membrane permeabilization of mitochondria via increasing bax translocation and inducing cytochrome C release, which activates the caspase cascade to induce apoptosis.
To investigate whether the caspase cascade modulated the role of hTERT, we treated si-hTERT T24/R2 cells with cisplatin in the presence of caspase inhibitors. While hTERT knock down increased membrane-bound bax and cytosolic cytochrome C, these effects were inhibited by caspase 8, 9, and particularly Z-VAD-FMK inhibitors (Fig. 3A) . Caspase inhibitors also blocked the increase in cisplatin-induced apoptosis induced by hTERT deficiency (Fig. 3B) .
DISCUSSION
Bladder cancer is the most common malignant neoplasm of the urinary system, with increasing morbidity and mortality. Most cases of bladder cancer initially respond to cisplatin-based combination chemotherapy, but acquired resistance usually occurs during disease progression [1] . Measuring The inhibition of telomerase in tumor cells represents a promising anticancer strategy, leading to telomere destabilization and consequent growth inhibition and cell death [18, 20, 26] . However, its effectiveness could be impaired by a lag phase, depending on the initial telomere length [27] .
Telomerase inhibition may take weeks or months of treatment to affect tumor cell growth [26, [28] [29] [30] . However, other studies show an immediate cellular response to telomerase inhibition regardless of telomere length [31] [32] [33] [34] [35] . Therefore, targeting telomerase expression could regulate cell proliferation and apoptosis independent of reducing telomere length.
We next explored whether hTERT could modify mitochondrial function using an siRNA specific for hTERT and mea- 
